Immunogen Inc., of Waltham, Mass., said partner Roche AG, of Basel, Switzerland, reported global sales of breast cancer drug Kadcyla (ado-trastuzumab emtansine) of CHF102 million (US$115 million) for the first quarter. Immunogen receives and recognizes royalties on Kadcyla sales after the quarter in which Roche records the sales. For the quarter ending March 31, Immunogen received $2.6 million in royalties received from Roche based on Kadcyla sales in the final quarter of 2013. Immunogen fell short of revenue and earnings-per-share estimates, reporting total revenues of $6.9 million vs. estimates of $13.3 million. The company posted a net loss of $37.5 million, or 44 cents per share, for the first three months of 2014. Analyst estimates had predicted a net loss of 27 cents per share. As of March 31, the firm had about $164.1 million in cash and equivalents. Shares of Immunogen (NASDAQ:IMGN) closed Friday at $12.39, down $1.40.